...
首页> 外文期刊>Translational Stroke Research >Treatment with the Iron Chelator, Deferoxamine Mesylate, Alters Serum Markers of Oxidative Stress in Stroke Patients
【24h】

Treatment with the Iron Chelator, Deferoxamine Mesylate, Alters Serum Markers of Oxidative Stress in Stroke Patients

机译:用铁螯合剂甲磺酸去铁胺治疗可改变中风患者血清氧化应激指标

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The iron chelator, deferoxamine mesylate (DFO), has shown neuroprotective effects, mediated via suppression of iron-induced hydroxyl radical formation, in various animal models of ischemic and hemorrhagic stroke. Therefore, the objective of this study was to investigate whether DFO can exert similar actions in stroke patients, by examining the effects of treatment with DFO on biological markers of oxidative stress, namely serum total hydroperoxides and lipoperoxides and total radical trapping antioxidant capacity (TRAP), in stroke patients. We found that serum levels of peroxides were reduced, and TRAP levels increased after a 3-day treatment with DFO (500 mg). These findings provide a preliminary proof of concept that DFO can exert potential antioxidant neuroprotective effects in stroke patients. Future, larger-scale, randomized, and controlled studies to further evaluate the safety and efficacy of DFO in patients with stroke are warranted.
机译:铁螯合剂甲磺酸去铁胺(DFO)在各种缺血性和出血性中风动物模型中均表现出了神经保护作用,通过抑制铁诱导的羟基自由基的形成而介导。因此,本研究的目的是通过检查DFO治疗对氧化应激的生物学指标,即血清总氢过氧化物和脂过氧化物和总自由基捕获抗氧化能力(TRAP)的影响,研究DFO是否可在中风患者中发挥类似作用。中风患者。我们发现用DFO(500 mg)治疗3天后,血清过氧化物水平降低,TRAP水平升高。这些发现为DFO可以在中风患者中发挥潜在的抗氧化神经保护作用提供了初步的概念证明。有必要进行进一步,大规模,随机和对照的研究,以进一步评估DFO在中风患者中的安全性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号